Ferring appoints Jan Lundberg to Group Board

Ferring appoints Jan Lundberg to Group Board
February 18, 2021 siddhant

Ferring appoints Jan Lundberg to Group Board

Saint-Prex, Switzerland – 18th February 2021 – Ferring Pharmaceuticals announced today that Jan Lundberg has been appointed to the Ferring Group Board, effective January 2021, as a non-executive director and Chairman of the Research and Development Committee, following the retirement of John Patterson.

“I would like to express my sincere appreciation for John’s commitment to Ferring, his considerable achievements, and his passion for science and innovation,” said Frederik Paulsen, Chairman of the Ferring Board of Directors. “I am delighted to welcome Jan to the Ferring Group Board and am confident that, with his strong scientific and medical background, Jan will provide significant value to Ferring and our patients as we move into our next phase of growth through innovation.”

Dr. Lundberg has 18 years’ leadership experience with global organisations such as AstraZeneca and Eli Lilly and supervised the discovery and development of more than 200 candidate drugs leading to 25 approved products across multiple therapeutic areas. He has also served on the boards of several biotechnology companies and on governmental committees in the EU and USA.

Dr. Lundberg holds M.D. and Ph.D. degrees, and before joining industry was Professor of Pharmacology at the Karolinska Institute in Sweden.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in speciality areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

For more information, please contact

Lindsey Rodger
Senior Manager, Corporate Communications
+41 79 191 0486 (mobile)
lindsey.rodger@ferring.com

0 Comments

Leave a reply

Your email address will not be published. Required fields are marked *

*

This page is not intended for patients or for members of the general public. It is only intended to be used by healthcare professionals.

OK

Cette page n'est pas destinée aux patients ou au grand public. Il est uniquement destiné à être utilisé par des professionnels de santé.

OK

Ik bevestig dat ik een professionele zorgverlener ben of een zakelijke relatie heb met Ferring Pharmaceuticals

OK

Ez az oldal nem betegeknek, vagy nagyközönségnek szól. Az oldalt kizárólag egészségügyi szakemberek használhatják.

OK

Ta strona nie jest przeznaczona dla pacjentów ani dla ogółu odwiedzających. Ta strona stworzona jest dla pracowników sektora ochrony zdrowia.

OK

Эта страница не предназначена для пациентов или для широкой публики. Она предназначена только для медицинских работников.

OK